Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Allogene Therapeutics
University of Chicago
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Incyte Corporation
Washington University School of Medicine
Incyte Corporation
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Massachusetts General Hospital
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Eastern Cooperative Oncology Group
Incyte Corporation
National Cancer Institute (NCI)
Incyte Corporation
Takeda
Juno Therapeutics, a Subsidiary of Celgene
UNC Lineberger Comprehensive Cancer Center
ADC Therapeutics S.A.
Celgene
Incyte Corporation
Seoul National University Hospital